NCT03277729 - A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 5, 2017

Primary Completion Date

March 29, 2024

Study Completion Date

November 16, 2037

Conditions

Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Lymphoplasmacytic LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaRefractory Lymphoplasmacytic LymphomaRefractory Mantle Cell LymphomaRefractory Transformed Non-Hodgkin LymphomaRecurrent Transformed B-Cell Non-Hodgkin LymphomaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Marginal Zone LymphomaRefractory Transformed B-Cell Non-Hodgkin LymphomaRefractory Transformed Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic LymphomaRecurrent Central Nervous System LymphomaRefractory Central Nervous System Lymphoma

Interventions

BIOLOGICAL

Chimeric Antigen Receptor T-Cell Therapy

Given CD20 CAR T cell IV

DRUG

Cyclophosphamide

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Leukapheresis

Undergo leukapheresis

DRUG

Fludarabine Phosphate

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle